Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415558 | 1.00 | S1PR5 (0.53) | S1PR5S1PR1L3MBTL1FUCA1HSD17B10 | |
| SCHEMBL16714074 | 0.84 | GRIN2D (0.56) | S1PR5S1PR1L3MBTL1HSD17B10SIGMAR1 | |
| SCHEMBL3815948 | 0.84 | GRIN2D (0.56) | S1PR5S1PR1L3MBTL1HSD17B10SIGMAR1 | |
| SCHEMBL3815944 | 0.84 | GRIN2D (0.56) | S1PR5S1PR1L3MBTL1HSD17B10SIGMAR1 | |
| SCHEMBL2706345 | 0.84 | MEN1 (0.46) | S1PR5S1PR1FUCA1GBA1SIGMAR1 | |
| SCHEMBL23464746 | 0.84 | MEN1 (0.46) | S1PR5S1PR1FUCA1GBA1SIGMAR1 | |
| SCHEMBL203039 | 0.84 | MEN1 (0.46) | S1PR5S1PR1FUCA1GBA1SIGMAR1 | |
| SCHEMBL17166392 | 0.81 | KMT2A (0.42) | S1PR5S1PR1L3MBTL1FUCA1ALDH1A1 | |
| SCHEMBL30419036 | 0.77 | S1PR5 (0.52) | S1PR5S1PR1L3MBTL1FUCA1GBA1 | |
| SCHEMBL27780998 | 0.75 | SIGMAR1 (0.51) | S1PR5S1PR1FUCA1SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-03-30 | — | — | US | disclosed |
| WO-2021108683-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-9156858-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | S1PR5 4163/4885S1PR1 4216/4885L3MBTL1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.